Peg-IFN alfa-2b

BIOLOGICAL5 trials

Sponsors

Merck Sharp & Dohme LLC, Hoffmann-La Roche

Conditions

Chronic Hepatitis CHIV InfectionsHepatitis CHepatitis C, Chronic

Phase 1

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

CompletedNCT01678131

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2012-10-30End: 2013-09-02Updated: 2022-08-26

Phase 4

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

TerminatedNCT01606800

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2013-01-01End: 2015-01-26Updated: 2018-10-25

Unknown Phase

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

TerminatedNCT00725842

Merck Sharp & Dohme LLCHepatitis C, Hepatitis C, Chronic

Start: 2009-01-31End: 2011-06-30Updated: 2015-09-21

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

CompletedNCT00736242

Merck Sharp & Dohme LLCChronic Hepatitis C, Hepatitis C, HIV Infections

Start: 2005-12-31End: 2011-12-31Updated: 2015-02-19

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

CompletedNCT01447446

Hoffmann-La RocheHepatitis C, Chronic

Start: 2011-09-30End: 2015-07-31Updated: 2017-03-30

Related Papers

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection

Clinical Pharmacology & Therapeutics2019-12-23